Catalog Products » CD96/TACTILE, His, Mouse
Manual
Manual
COAs

CD96/TACTILE, His, Mouse

The receptors CD96 and TIGIT are expressed on the surface of T and natural killer (NK) cells, and recent studies suggest both play important inhibitory roles in immune function. CD96 has been shown to modulate immune cell activity in mice, with Cd96-/- mice displaying hypersensitive NK-cell responses to immune challenge and significant tumor resistance. The counterbalance between the putative inhibitory CD96 and TIGIT receptors and the activating receptor, CD226, offers unique strategies for immuno-oncology drug development.
$390.00
Z04333-100

Ask us a question
Product Introduction
Species Mouse
Protein Construction
CD96/TACTILE (Val22-Met536)
Accession # Q3U0X8		 His
N-term C-term
Purity > 95% as determined by Bis­Tris PAGE 
Endotoxin Level Less than 1EU per μg by the LAL method.
Expression System HEK293
Theoretical Molecular Weight 57.9 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 90-130 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles.
Back

CD96/TACTILE, His, Mouse

The purity of CD96/TACTILE, His, Mouse is greater than 95% as determined by SEC-HPLC. »

CD96/TACTILE, His, Mouse

CD96/TACTILE, His, Mouse on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »

<
>

Background
Target Background The receptors CD96 and TIGIT are expressed on the surface of T and natural killer (NK) cells, and recent studies suggest both play important inhibitory roles in immune function. CD96 has been shown to modulate immune cell activity in mice, with Cd96-/- mice displaying hypersensitive NK-cell responses to immune challenge and significant tumor resistance. The counterbalance between the putative inhibitory CD96 and TIGIT receptors and the activating receptor, CD226, offers unique strategies for immuno-oncology drug development.
Synonyms CD96 molecule; CD96; DKFZp667E2122; TACTILE
Back

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.